HeartBeam, Inc. Price & Performance (BEAT)

HeartBeam reported significant progress in the first months of 2025, securing FDA 510(k) clearance for its cardiac monitoring system and launching an Early Access Program. The company also presented positive clinical study results and closed a public offering, raising $11.5 million to support commercialization and further research.123

HeartBeam successfully completed a public offering, raising approximately $11.5 million after exercising an over-allotment option. This funding, driven by strong institutional demand, provides the company with critical resources for commercial-readiness, ongoing R&D, and regulatory initiatives as it prepares for U.S. market entry.345

Institutional investors now hold over 2.7 million shares of HeartBeam, reflecting increased confidence in the company’s prospects. Despite a 24% stock price decline over the past year, recent capital raises and regulatory milestones have positioned HeartBeam for potential growth in the competitive cardiac monitoring sector.67